We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
2
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
FDA
Food and Drug Administration
• A Phase II clinical trial is evaluating mycophenolate mofetil's efficacy and safety in patients with high-grade locally advanced or metastatic osteosarcoma. • The trial aims to determine progression-free survival at 16 weeks as the primary endpoint, with secondary endpoints including overall survival and safety parameters. • Mycophenolate mofetil, an immunosuppressant, has shown anticancer activity against osteosarcoma in preclinical studies, warranting further investigation in humans. • The study involves multiple centers in Thailand and includes adolescent and adult patients who have progressed after standard chemotherapy or are not candidates for it.
